Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2026 | UNION: short-course radiotherapy plus camrelizumab and CAPOX in LARC

David Tougeron, MD, PhD, Poitiers University Hospital, Poitiers, France, discusses the findings from the UNION trial (NCT04928807) of short-course radiotherapy plus neoadjuvant and adjuvant capecitabine and oxiplatin (CAPOX) with neoadjuvant and adjuvant camrelizumab vs long-course chemoradiotherapy with neoadjuvant and adjuvant CAPOX in locally advanced rectal cancer (LARC). The trial demonstrated a significant increase in pathological complete response rate, from 40% to 50%, and event-free survival at three years, from 77% to 91%. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.